Michael Goldman

Biography
Dr. Goldman did his undergraduate work in Biology at the University of Rochester, and obtained a Ph.D. in evolutionary biology at Purdue University, and completed two fellowships in Medical Genetics, at Baylor College of Medicine in Houston and the University of Washington in Seattle. Dr. Goldman joined the faculty at San Francisco State University in 1988, and has served as Chair of the Department of Biology and the University Academic Senate. Dr. Goldman teaches general genetics and evolution for biology majors, developmental biology for CellMolecular Biology majors, and an interdisciplinary course on the ethical issues in science and technology. Research is in chromatin structure and the regulation of gene expression during mammalian development. Dr. Goldman sees the public understanding of science as a key need if science and society are to thrive.

---

Talk
NA - Track Chair
NA - Track Chair

Stefan Horvath

Biography
Dr. Steve Horvath is a geroscientist and computational biologist best known for developing the epigenetic clock, a groundbreaking biomarker that measures biological aging based on DNA methylation patterns. His work has transformed aging research, enabling precise tracking of aging-related interventions and influencing diagnostics, longevity science, and precision medicine. Dr. Horvath has led key studies linking epigenetic age acceleration to disease risk and mortality, paving the way for potential anti-aging therapies. He has held leadership roles in major scientific initiatives and has received numerous honors, including election to the Academy for Health & Lifespan Research, as well as the Nathan W. Shock Award for aging research. His contributions continue to shape the future of aging and longevity research, with broad applications in medicine and biotechnology.

---

Talk
Pioneering the Epigenetic Clock: Advancing Aging and Longevity Science

Nir Barzilai

Biography
Dr. Nir Barzilai is a preeminent leader in geroscience, demonstrating in his studies that aging has its own biology that drives age-related diseases, a process that can be targeted. At Albert Einstein College of Medicine, he is a professor in the departments of Medicine and Genetics, the director of the Institute for Aging Research, and the director of the Einstein-National Institutes of Health (NIH) Nathan Shock Center of Excellence in the Basic Biology of Aging, and the author of more than 350 papers. He made seminal discoveries in extending the health and lifespan of animals and discovering pathways for exceptional longevity in humans. He is leading an international effort to approve drugs targeting aging. Targeting Aging with Metformin (TAME) is a specific study conceived by Dr. Barzilai to prove that a single drug can combat multiple diseases associated with aging and get FDA approval for targeting aging. Dr. Barzilai is a co- founder and the President of AHLS. He is also on the board of directors of the American Federation for Aging Research, where he co-leads its biomarker effort (FAST), TAME, and Super Agers initiative. He is an Executive of the Longevity Biotech Association (LBA) and serves on the Healthy Longevity Medicine Society council. He authored Age Later: Health Span, Life Span, and the New Science of Longevity.

David Sinclair

Biography
David A. Sinclair, A.O., Ph.D. is one of the worlds mostinfluential scientists and a leading figure in the study of humanlongevity. A tenured Professor of Genetics at Harvard Medical School, he best known for his research on the role of sirtuins, NAD+ metabolism, and aging as information loss. In 2020, his lab reported successful use of reprogramming to safely reverse aging in mammals. Professor Sinclair served as Founding Director of the Glenn Center forBiology of Aging Research at Harvard and has published over 200 articles cited 100,000 times. He is inventor on more than 50 patents and has co-founded over a dozensuccessful companies including MetroBiotech and Life Biosciences. He is a New York Times bestselling author of Lifespan and the host of Lifespan. Among 36 awards, he was recognized as oneof TIME Magazines 100 Most Influential People, Noble Genius PrizeOfficer of the Order of Australia (A.O.)

---

Talk
Age reversal in the clinic: How safe? How soon?
Dr. Sinclair will be presenting his latest research and clinical update on making safe age reversal possible

Y. Ryan Lu

Biography
Yuancheng Ryan Lu is a leading early-career investigator in aging research. His research focuses on the genetic and epigenetic foundations of aging and its reversal, using the eye as a model system. During his PhD with David Sinclair at Harvard, he developed an AAV-based in vivo reprogramming approach that rejuvenated retinal neurons and restored vision in aging and glaucoma models (Nature, 2020). This work helped establish age reversal as a tractable therapeutic concept and provided experimental support for the theory that aging is reversible process driven by loss of epigenetic information (Nature Aging, 2023). In his postdoctoral work with Jonathan Weissman, he has advanced the field beyond reprogramming as a tool by integrating genome-scale perturbation screens to identify downstream causal effectors (bioRxiv, 2025), thereby clarifying underlying mechanisms while nominating safer and more precise rejuvenation therapies. He is also co-developing machine learningguided approaches to discover novel rejuvenation factors.

Jay Olshansky

Biography
Jay Olshansky received his Ph.D. in Sociology at the University of Chicago in 1984. He is currently a Professor in the School of Public Health at the University of Illinois at Chicago, Research Associate at the Center on Aging at the University of Chicago and at the London School of Hygiene and Tropical Medicine, and Chief Scientist at Lapetus Solutions, Inc. The focus of his research to date has been on estimates of the upper limits to human longevity, exploring the health and public policy implications associated with individual and population aging, forecasts of the size, survival, and age structure of the population, pursuit of the scientific means to slow aging in people (The Longevity Dividend), and global implications of the re-emergence of infectious and parasitic diseases. Dr. Olshansky is on the Board of Directors of the American Federation of Aging Research; he is the first author of The Quest for Immortality: Science at the Frontiers of Aging (Norton, 2001) and A Measured Breath of Life (2013); and co-edited Aging: The Longevity Dividend (Cold Spring Harbor Laboratory Press, 2015). In 2016, Dr. Olshansky was honored with the Donald P. Kent Award from the Gerontological Society of America, the Irving S. Wright Award from the American Federation for Aging Research, and he was named one of Next Streets Influencer in Aging.

Sherry Zhang

Biography
Yi Sherry Zhang is a genomics scientist and health-tech entrepreneur advancing the translation of longevity science into scalable population impact. At the Buck Institute for Research on Aging, she leads the development of Healthspan Horizons, a federated AI and biodata platform integrating multi-omics, digital, and clinical signals to quantify and extend healthy human lifespan. Drawing on nearly two decades of experience at the intersection of molecular science, data intelligence, and personalized health, she previously founded GenoPalate, which built one of the worlds largest nutrigenomics databases and consumer platforms for precision nutrition. Her work bridges molecular biomarkers and actionable lifestyle insights, with publications and features spanning scientific and public domains. An advocate for equitable access to scientific wellness, she speaks globally on data federation, precision aging, and the future of healthspan intelligence.

David A. Sinclair

Biography
David A. Sinclair, A.O., Ph.D. is considered one of the worlds mostinfluential scientists and a leading figure in the study of humanlongevity. He is a tenured Professor of Genetics at Harvard Medical School(Boston, MA, USA) and Co-FounderCo-Chief Editor of the scientificjournal Aging.Professor Sinclairs pioneering work in genetics and aging biology hasfundamentally shaped the worlds understanding of mechanisms of aging andage-related diseases. He is best known for his research on the molecularbiology of aging, particularly the role of sirtuins, NAD+ metabolism, andepigenetic changes in regulating the aging process. In 2020, the SinclairLab reported successful use of cellular reprogramming to safely reverseaging in mammals, which they showed could cure blindness in animal models.Professor Sinclair served as Founding Director of the Glenn Center forBiology of Aging Research at Harvard Medical School from 20042023 andhas published over 400 articles that have been cited 100,000 times. He isthe inventor on more than 50 patents and has co-founded over a dozensuccessful companies including MetroBiotech, EdenRoc Sciences, FullyAligned Company, and Life Biosciences.Professor Sinclair is the New York Times bestselling author of Lifespan:Why We Age-And Why We Dont Have To and the host of the Lifespan with Dr.David Sinclair podcast, a 1 show on Apple that provides health and scienceeducation.Among over 35 career awards, Professor Sinclair has been recognized as oneof TIME Magazines 100 Most Influential People In The World, one of TIMEs50 Most Influential People In Health Care, received the Pioneer Award fromthe Director of the NIH, The Noble Genius Prize from The World Forum, andwas appointed by Queen Elizabeths representative as Officer of the Orderof Australia(A.O.) for his contributions to scientific research, sciencecommunication, and national security.

Nir Barzilai

Biography
Dr. Nir Barzilai is a preeminent leader in geroscience, demonstrating inhis studies that aginghas its own biology that drives age-related diseases, a process that can betargeted. At AlbertEinstein College of Medicine, he is a professor in the departments ofMedicine and Genetics,the director of the Institute for Aging Research, and the director of theEinstein-NationalInstitutes of Health (NIH) Nathan Shock Center of Excellence in the BasicBiology of Aging, andthe author of 350 papers. He made seminal discoveries in extending thehealth and lifespan ofanimals and discovering pathways for exceptional longevity in humans. He isleading aninternational effort to approve drugs targeting aging. Targeting Aging withMetformin (TAME) isa specific study conceived by Dr. Barzilai to prove that a single drug cancombat multiplediseases associated with aging and get FDA approval for targeting aging.Dr. Barzilai is a co-founder and the President of AHLS. He is also on the board of directors ofthe AmericanFederation for Aging Research, where he co-leads its biomarker effort(FAST), TAME, andSuper Agers initiative. He is an Executive of the Longevity BiotechAssociation (LBA) andserves on the Healthy Longevity Medicine Society council. He authored AgeLater: Health Span,Life Span, and the New Science of Longevity.

Stefan Horvath

Biography
Dr. Steve Horvath is a geroscientist and computational biologist best knownfor developing the epigenetic clock, a groundbreaking biomarker thatmeasures biological aging based on DNA methylation patterns. His work hastransformed aging research, enabling precise tracking of aging-relatedinterventions and influencing diagnostics, longevity science, and precisionmedicine. Dr. Horvath has led key studies linking epigenetic ageacceleration to disease risk and mortality, paving the way for potentialanti-aging therapies. He has held leadership roles in major scientificinitiatives and has received numerous honors, including election to theAcademy for HealthLifespan Research, as well as the Nathan W. ShockAward for aging research. His contributions continue to shape the future ofaging and longevity research, with broad applications in medicine andbiotechnology.

Alex Zhavoronkov

Biography
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leading clinical-stage biotechnology company developing next-generation generative artificial intelligence and robotics platforms for drug discovery. Under his leadership, Insilico raised over $400 million in multiple rounds from expert biotechnology, healthcare, and financial investors, opened RD centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Since 2021, the company nominated 21 preclinical candidates, started 6 human clinical trials, and entered Phase II with an AI-discovered novel target and AI-designed novel molecule.Since 2012, he has published over 200 peer-reviewed research papers and 3 books. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Nathan Price

Biography
Nathan Price focuses on advancing AI-enabled scientific wellness and bringing precision medicine into proactive practice. His work integrates multi-omics, digital biomarkers, and computational modeling to detect early signals of aging, resilience, and diseaseand to translate them into personalized, actionable guidance. He is building next-generation AI platforms designed to operationalize precision health at scale.Price has authored 220 scientific publications and led landmark longitudinal wellness studies. He co-authored The Age of Scientific Wellness. He has written for major outlets including The Wall Street Journal, LA Times, and Scientific American, and been a guest on leading podcasts such as Armchair Expert, The Doctors Farmacy, and Keeping It Real with Jillian Michaels. His recognitions include being an Emerging Leader for the National Academy of Medicine, service on the National Academies Board on Life Sciences, Fellowship in AIMBE, and the 2023 AlexanderMildred Seelig Award from the American Nutrition Association.

Michael Gurven

Biography
Professor Gurven's research links the evolved life history of humans with high levels of intragroup cooperation. He has conducted fieldwork for two decades with South American indigenous populations, and his work takes an evolutionary perspective on behavior, health, physiology and psychology. Since 2002, Gurven has co-directed the Tsimane Health and Life History Project to better understand how aspects of environment and lifestyle affect health and lifespan in subsistence-level societies. His research applies an evolutionary lens to help inform our understanding of todays complex diseases. His current research in biodemography and health disparities helps understand environmental and social impacts on growth, development and aging across the lifespan. He also focuses on how acculturation and market integration have impacted demographic and social patterns, and chronic disease risk (e.g. heart disease, diabetes, dementia) among indigenous populations.

Anthony Iton

Biography
Dr. Tony Iton is a Lecturer of Health PolicyManagement at UC Berkeleys School of Public Health. He is also a Senior Vice President for Healthy Communities at The California Endowment. In the fall of 2009, he began to oversee the organizations 10-Year, multimillion-dollar statewide commitment to advance policies and forge partnerships to build healthy communities and a healthy California. Iton serves on the board of directors of the Public Health Institute, the Public Health Trust, the Prevention Institute and Jobs For The Future. In the past, he has served as both the director and County Health Officer for the Alameda County Public Health Department. In that role, he oversaw the creation of an innovative public health practice designed to eliminate health disparities by tackling the root causes of poor health that limit the quality of life and lifespan in many of Californias lowincome communities. He has worked as an HIV disability rights attorney at the Berkeley Community Law Center, a health care policy analyst with Consumers Union West Coast Regional Office, and as a physician and advocate for the homeless at the San Francisco Public Health Department.Dr. Itons primary focus includes health of disadvantaged populations and the contributions of race, class, wealth, education, geography and employment to health status. His awards include the Champion of Children Award from the United Way and the National Association of City and County Health Officials Award of Excellence for the use of information technology in public health. In February 2010, Dr. Iton was recognized by the California Legislative Black Caucus with the Black History Month Legends Award and presented on the floor of the California State Assembly with a resolution memorializing his lifes work and achievements.

Varun Dwaraka

Biography
Varun Dwaraka is a computational epigenetics scientist and Fellow of the Royal Society of Biology, known for translating DNA methylation data into practical tools for aging and disease-risk prediction. His work focuses on multi-omic epigenetic clocks, epigenetic biomarker proxies; methylation-derived surrogates of proteins, metabolites, and clinical labs that make results interpretable), and methylation risk scores, which quantify long-term risk for specific conditions, often years before clinical onset. He has led research published in top journals including Nature Aging, Genome Medicine, BMC Medicine, and Advanced Science. His work has reached broad audiences through features in Forbes, BBC, The Times of London, Newsweek, The Aesthetic Magazine, and Mens Health, and in the Emmy Awardwinning documentary You Are What You Eat, along with health and science podcasts. He is also a full member of Sigma Xi and a 2023 Foresight Fellow in Biotechnology and Health Expansion.

---

Talk
Leveraging Epigenetic Testing: From Clocks to Risk
Epigenetic testing has evolved beyond a single biological age number. This talk shows how TruDiagnostic progressed from epigenetic clocks to epigenetic biomarker proxies, methylation-derived surrogates of proteins, metabolites, and clinical lab, and finally to methylation risk scores that quantify disease risk years before onset, enabling actionable, interpretable precision longevity.

Ranjan Sinha

Biography
Ranjan Sinha is an entrepreneur, author, innovator, and pioneer inPrecision Biology. He is passionate about AI, microbiome, andgenomics-based care.After successfully addressing a life-threateningcondition using precision biology, Ranjan turned a personalnecessitysupported by leading clinicians and scientistsinto a mission tomake chronic illness optional.He holds multiple patents in biomarkers,genetics, gut microbiome, AI, and human metabolism.A Wharton alumnus andtrained engineer, Ranjan is a published scientist, author, and avidcyclist. He formerly worked at Apple and built large data, HRconsumerfood companies. He is a member of the American College of LifestyleMedicine and the American College of Gastroenterology, and a frequentspeaker on topics including longevity, metabolic health, food, and thescaled application of precision medicine.

Mahdi Moqri

Biography
Dr. Mahdi Moqri is a faculty member at Harvard Medical School and an independent investigator at the Division of Genetics as well as the Endocrinology, Diabetes, and Metabolism. His research integrates omics, bioinformatics, and computational methods to uncover the molecular mechanisms of aging and to develop new approaches for early detection and prevention of age-related diseases. Dr. Moqri co-directs the Biomarkers of Aging Consortium (agingconsortium.org), where he leads efforts to develop blood-based biomarkers of aging using large-scale omics datasets and longitudinal biobank resources. He completed his postdoctoral fellowship at Stanford University in the Snyder Lab, and his formal training is in computer science and informatics. Dr. Moqri looks forward to starting new collaborations with colleagues across the division.

Martin Jensen

Biography
Martin Jensen works to make aging a good thing. Our bodies have the capacity for rejuvenation, but we havent yet mastered the biology that makes this happen. Biology is full of feedback loops that cause non-linear responses, which makes it difficult to go from experimental observations to reliably producing specific physiological outcomes.Dr. Jensen's focus is on technological and organizational progress towards solving biological problems faster than they arise. This involves developing technologies to interrogate the full network of aging processes inside living organisms, and finding ways to predict future health from todays measurements.Previously, Dr Jensen was an academic working on a range of cellular mechanisms involved in aging: mitochondrial function, NAD metabolism, DNA damage signaling and other stress responses.